GE HealthCare has announced a leadership transition for its China operations, with Will Song to succeed Yihao Zhang as new president and CEO.

Song is set to join the company on 1 April 2025, and will take on leadership responsibilities for the region beginning 1 July, following the departure of Yihao.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

His previous role was at Johnson & Johnson (J&J) China, where he served as chairman and global senior vice-president.

Song served in leadership roles within industry associations in China and contributed to the healthcare industry and broader economic development.

He has held the positions of vice-chairman of the China Association of Medical Devices Industry and the Shanghai Enterprises Directors Association, and vice-president at the China Association of Enterprises with Foreign Investment.

As part of the transition, Song will be based in Shanghai, working closely with Zhang over the coming months to ensure a smooth handover and to align with GE HealthCare’s strategic growth objectives.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

GE HealthCare CEO and president Peter Arduini said: “Looking ahead, I am confident that Will’s stellar reputation and in-depth knowledge of the China market, along with his robust relationships with key stakeholders and deep understanding of our customer base, will help enhance our position in China and move the region forward to effectively deliver on the future of healthcare.”

During his tenure since 2019, Zhang has played a pivotal role in steering the company’s strategic development and operations in China.

His initiatives have included doubling the investment in innovation in five years and expanding the manufacturing presence in areas such as Shanghai, Tianjin, Beijing, and Wuxi; as well as establishing new sites in Shenzhen and Chengdu.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact